CoChat

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial

Open access
Karim, Quarraisha Abdool, Kharsany, Ayesha BM, Frohlich, Janet A, Baxter, Cheryl, Yende, Nonhlanhla, Mansoor, Leila E, Mlisana, Koleka P, Maarschalk, Silvia, Arulappan, Natasha, Grobler, Anneke, Sibeko, Sengeziwe, Omar, Zaheen, Gengiah, Tanuja N, Mlotshwa, Mukelisiwe, Samsunder, Natasha, Abdool Karim, Salim S · 2011 · Trials
Cited by 37

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for sexually active women who are unable to successfully negotiate mutual monogamy or condom use. Purpose: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa. Methods: This analysis assessed the baseline demographic, clinical and sexual behavior data of women screened and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as means and percent for categorical variables. Results: HIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in exchange for sex (p < 0.001). Conclusion: The populations selected provide suitable diverse target groups for HIV prevention intervention studies. Trial registration: ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT00441298

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1745-6215-12-67

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 37

Metadata

Authors
Karim, Q. A., Kharsany, A. B., Frohlich, J. A., Baxter, C., Yende, N., Mansoor, L. E., Mlisana, K. P., Maarschalk, S., Arulappan, N., Grobler, A., Sibeko, S., Omar, Z., Gengiah, T. N., Mlotshwa, M., Samsunder, N., & Abdool Karim, S. S.
Venue
Trials
Published
2011-03-07
Volume
12
Issue
1
Pages
67-67
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2114527378
Cited by
37
References
5
FWCI
3.80
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. https://app.cochat.ai/papers/10.1186/1745-6215-12-67
The paper
Karim, Q. A., Kharsany, A. B., Frohlich, J. A., Baxter, C., Yende, N., Mansoor, L. E., Mlisana, K. P., Maarschalk, S., Arulappan, N., Grobler, A., Sibeko, S., Omar, Z., Gengiah, T. N., Mlotshwa, M., Samsunder, N., & Abdool Karim, S. S. (2011). Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials. https://doi.org/10.1186/1745-6215-12-67

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.